Denali Therapeutics

(NASDAQ) DNLI

Current Price$19.68

Market Cap$3.11B

Since IPO (2017)-9%

5 Year-64%

1 Year+36%

1 Month+0%

Denali Therapeutics Financials at a Glance

Market Cap

$3.11B

Revenue (TTM)

$0.00

Net Income (TTM)

$508.02M

EPS (TTM)

$-2.88

P/E Ratio

-6.81

Dividend

$0.00

Beta (Volatility)

1.62 (High)

Dividend

$0.00

Beta (Volatility)

1.62 (High)

Price

$19.68

Volume

1,945,846.02

Open

$19.44

Price

$19.68

Volume

1,945,846.02

Open

$19.44

Previous Close

$19.62

Daily Range

$19.44 - $20.53

52-Week Range

$12.58 - $23.77

Dividend

$0.00

Beta (Volatility)

1.62 (High)

Price

$19.68

Volume

1,945,846.02

Open

$19.44

Previous Close

$19.62

Daily Range

$19.44 - $20.53

52-Week Range

$12.58 - $23.77

DNLI News

Page 1

DNLI: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Denali Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

507

CEO

Ryan J. Watts, PhD

Website

www.denalitherapeutics.com

Headquarters

South San Francisco, CA 94080, US

DNLI Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-50%

Return on Capital

-47%

Return on Assets

-40%

Earnings Yield

-14.68%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.11B

Shares Outstanding

158.66M

Volume

1.95M

Avg. Volume

1.73M

Financials (TTM)

Gross Profit

$11.18M

Operating Income

$555.34M

EBITDA

$497.63M

Operating Cash Flow

$412.60M

Capital Expenditure

$9.50M

Free Cash Flow

$422.10M

Cash & ST Invst.

$867.88M

Total Debt

$42.29M

Denali Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$3.11B

N/A

Market Cap/Employee

$7.03M

N/A

Employees

443

N/A

Net Income

$128.45M

+3.4%

EBITDA

$137.36M

+3.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$957.50M

+24.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$30.19M

-24.6%

Short Term Debt

$0.00

-100.0%

Return on Assets

-40.13%

N/A

Return on Invested Capital

-47.33%

N/A

Free Cash Flow

$133.67M

+2.1%

Operating Cash Flow

$131.20M

+0.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BEAMBeam Therapeutics Inc.

BEAMBeam Therapeutics Inc.$32.32+2.70%

RCUSArcus Biosciences, Inc.

RCUSArcus Biosciences, Inc.$25.36+2.34%

LQDALiquidia Corporation

LQDALiquidia Corporation$42.30+0.05%

ETNB89bio, Inc.

ETNB89bio, Inc.$14.84+0.00%

GLPGGalapagos N.V.

GLPGGalapagos N.V.$28.62+3.21%

AGIOAgios Pharmaceuticals, Inc.

AGIOAgios Pharmaceuticals, Inc.$27.79+0.94%

RXRXRecursion Pharmaceuticals, Inc.

RXRXRecursion Pharmaceuticals, Inc.$3.32+1.53%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

RXTRackspace Technology

RXTRackspace Technology$5.49+0.56%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.62+0.08%

NOKNokia

NOKNokia$12.82+0.04%

RKLBRocket Lab

RKLBRocket Lab$105.47+0.34%

POETPoet Technologies

POETPoet Technologies$10.95+0.14%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.28+0.07%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.57-0.07%

Questions About DNLI

What is the current price of Denali Therapeutics?

Denali Therapeutics is trading at $19.62 per share.

What is the 52-week range for Denali Therapeutics?

Over the past 52 weeks, Denali Therapeutics has traded between $12.58 and $23.77.

How much debt does Denali Therapeutics have?

As of the most recent reporting period, Denali Therapeutics reported total debt of $40.05M.

How much cash does Denali Therapeutics have on hand?

Denali Therapeutics reported $387.63M in cash and cash equivalents in its most recent financial results.

What is Denali Therapeutics’s dividend yield?

Denali Therapeutics does not currently have a dividend yield.

Denali Therapeutics

Denali Therapeutics Financials at a Glance

DNLI News

Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval

Why Shares of Denali Therapeutics Are Up Monday

Why Denali Therapeutics' Stock Rose 6.6% on Wednesday

Why Denali Therapeutics Stock Is Sinking This Week

Why Denali Therapeutics Stock Is Sinking Today

Why Denali Therapeutics Stock Popped Today

3 Best Biotech Stocks to Buy in November

Sanofi and Denali Halt Clinical Trials of Alzheimer Drug

DNLI: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Denali Therapeutics

DNLI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Denali Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About DNLI

What is the current price of Denali Therapeutics?

What is the 52-week range for Denali Therapeutics?

How much debt does Denali Therapeutics have?

How much cash does Denali Therapeutics have on hand?

What is Denali Therapeutics’s dividend yield?

Premium Investing Services